Remodeling tumor immunosuppressive microenvironment through dual activation of immunogenic panoptosis and ferroptosis by H2S-amplified nanoformulation to enhance cancer immunotherapy
Authors:
- Yingli LuoYLYingli Luo
- Maoyuan LinghuMLMaoyuan Linghu
- Xianyu LuoXLXianyu Luo
- Dongdong LiDLDongdong Li
- Jilong WangJWJilong Wang
- Shaojun PengSPShaojun Peng
- Yinchu MaYMYinchu Ma
Open Access
- 16 December 2024
- journal article
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (3) , 1242-1254
Abstract
No abstract availableKeywords
Funding Information
- Basic and Applied Basic Research Foundation of Guangdong Province (2021A1515220033)
- Fundamental Research Funds for the Central Universities (JUSRP123079, JUSRP123078)
- China Academy of Space Technology
- National Natural Science Foundation of China (82172073, 52103164)
This publication has 51 references indexed in Scilit:
- Enhancing cancer immunotherapy: Nanotechnology-mediated immunotherapy overcoming immunosuppressionActa Pharmaceutica Sinica B, 2024
- Unveiling ferroptosis as a promising therapeutic avenue for colorectal cancer and colitis treatmentActa Pharmaceutica Sinica B, 2024
- An iron-based metal-organic framework nanoplatform for enhanced ferroptosis and oridonin delivery as a comprehensive antitumor strategyActa Pharmaceutica Sinica B, 2024
- Engineering nanomedicines for immunogenic eradication of cancer cells: Recent trends and synergistic approachesActa Pharmaceutica Sinica B, 2024
- Radiation-based immunogenic vaccine combined with a macrophage “checkpoint inhibitor” for boosting innate and adaptive immunity against metastatic colon cancersActa Pharmaceutica Sinica B, 2024
- Self-driven nanoprodrug platform with enhanced ferroptosis for synergistic photothermal-IDO immunotherapyBiomaterials, 2023
- On-demand integrated nano-engager converting cold tumors to hot via increased DNA damage and dual immune checkpoint inhibitionActa Pharmaceutica Sinica B, 2022
- Tumor‐Microenvironment‐Responsive Nanomedicine for Enhanced Cancer ImmunotherapyAdvanced Science, 2021
- Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapyBiomaterials, 2021
- IDO-inhibitor potentiated immunogenic chemotherapy abolishes primary tumor growth and eradicates metastatic lesions by targeting distinct compartments within tumor microenvironmentBiomaterials, 2021